Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Buy" from Analysts

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has been given a consensus rating of "Buy" by the seven ratings firms that are covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $18.50.

A number of research firms have commented on KYTX. HC Wainwright raised shares of Kyverna Therapeutics from a "neutral" rating to a "buy" rating and upped their target price for the company from $4.00 to $5.00 in a research report on Tuesday, May 27th. Morgan Stanley decreased their target price on shares of Kyverna Therapeutics from $40.00 to $20.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 1st.

Kyverna Therapeutics Trading Up 10.3%

Shares of KYTX opened at $3.11 on Thursday. Kyverna Therapeutics has a 12-month low of $1.78 and a 12-month high of $11.40. The firm has a 50-day moving average price of $2.70 and a 200 day moving average price of $2.77. The firm has a market capitalization of $134.41 million, a P/E ratio of -0.92 and a beta of 2.95.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($1.03) EPS for the quarter, beating analysts' consensus estimates of ($1.21) by $0.18. Equities research analysts predict that Kyverna Therapeutics will post -3.29 earnings per share for the current fiscal year.

Institutional Trading of Kyverna Therapeutics

Hedge funds have recently made changes to their positions in the business. Gilead Sciences Inc. acquired a new stake in Kyverna Therapeutics in the fourth quarter valued at approximately $15,432,000. Jacobs Levy Equity Management Inc. raised its holdings in Kyverna Therapeutics by 2,225.0% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 461,959 shares of the company's stock valued at $1,728,000 after acquiring an additional 442,090 shares in the last quarter. Peapod Lane Capital LLC acquired a new stake in Kyverna Therapeutics in the first quarter valued at approximately $765,000. Integral Health Asset Management LLC raised its holdings in Kyverna Therapeutics by 75.0% in the fourth quarter. Integral Health Asset Management LLC now owns 350,000 shares of the company's stock valued at $1,309,000 after acquiring an additional 150,000 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Kyverna Therapeutics by 21.7% in the fourth quarter. Geode Capital Management LLC now owns 539,682 shares of the company's stock valued at $2,019,000 after acquiring an additional 96,370 shares in the last quarter. Institutional investors and hedge funds own 18.08% of the company's stock.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.